Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03673124 · FLOW

Participant flow

Ribociclib and Letrozole Treatment in Ovarian Cancer · Source last updated 2025-12-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Ribociclib 600 mg administered orally daily for 21 days followed by 7 days off in 28-day treatment cycle in combination with Letrozole 2.5 mg administered orally daily for 28 days. Treatment continues until disease progression or unacceptable toxicity.
    id
    FG000
    title
    Ribociclib and Letrozole
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Eligible with no protocol therapy
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        51
      comment
      Enrolled and eligible
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        49
      comment
      Eligible and treated
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        2
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
A total of 74 participants were screened for eligibility in the study. Out of these, 51 participants were determined to be eligible for enrollment. The recruitment period spanned from June 2018 to February of 2023.The first patient was enrolled on May 20, 2019.
Complete source fields
groups
  1. description
    Ribociclib 600 mg administered orally daily for 21 days followed by 7 days off in 28-day treatment cycle in combination with Letrozole 2.5 mg administered orally daily for 28 days. Treatment continues until disease progression or unacceptable toxicity.
    id
    FG000
    title
    Ribociclib and Letrozole
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Eligible with no protocol therapy
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        51
      comment
      Enrolled and eligible
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        49
      comment
      Eligible and treated
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        2
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
A total of 74 participants were screened for eligibility in the study. Out of these, 51 participants were determined to be eligible for enrollment. The recruitment period spanned from June 2018 to February of 2023.The first patient was enrolled on May 20, 2019.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice